SEMAGLUTIDE

The studies concern specified pharmaceutical preparations and eligibility criteria. The clinical record must remain separate from the identity, content and release status of a research vial.

STEP 1 randomised 1,961 adults with overweight or obesity, without diabetes, to semaglutide or placebo alongside lifestyle intervention for 68 weeks. The trial reported greater weight reduction with semaglutide. This result applies to the tested intervention and population, not every formulation or research material. [1]

SELECT enrolled 17,604 adults with established cardiovascular disease and overweight or obesity, without diabetes. The primary cardiovascular outcome occurred in 6.5% versus 8.0% with placebo; the hazard ratio was 0.80. This is evidence in a secondary-prevention population, not proof of the same benefit in people without cardiovascular disease. [2]

SURMOUNT-5 (2025) randomised 751 adults with obesity without type 2 diabetes to tirzepatide or semaglutide in an open-label, 72-week trial. The primary endpoint was percentage weight change. Tirzepatide produced greater reduction under the tested regimens; gastrointestinal events were the most common adverse events in both groups. This is a direct comparison, unlike comparisons assembled from separate placebo-controlled studies. [3]

SELECT reported permanent discontinuation due to adverse events in 16.6% with semaglutide and 8.2% with placebo. Benefit and tolerability must be read together; these trial data do not certify the safety of a supplied research material. [2]

Further updates should identify the new population, formulation and endpoint explicitly, with the full citation and safety context.